1. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group.
- Author
-
Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, and Fivush BA
- Subjects
- Anti-Inflammatory Agents therapeutic use, Antibodies, Viral blood, Antibody Formation immunology, Canada, Chickenpox Vaccine adverse effects, Child, Child, Preschool, Enzyme-Linked Immunosorbent Assay, Female, Herpesvirus 3, Human immunology, Humans, Immunization Schedule, Male, Nephrotic Syndrome blood, Nephrotic Syndrome drug therapy, Prednisone therapeutic use, Prospective Studies, Safety, United States, Chickenpox Vaccine immunology, Nephrotic Syndrome immunology
- Abstract
Objective: To evaluate the safety and immunogenicity of varicella vaccine in children with nephrotic syndrome, including those taking low-dose, alternate-day prednisone., Study Design: Prospective, open-label, multicenter clinical trial of varicella vaccine in a 2-dose regimen in US and Canadian children (12 months to <18 years) with nephrotic syndrome. Varicella Zoster Virus (VZV) antibody levels were measured after the first and second vaccine dose and yearly for 2 years. Patients were monitored for adverse reactions to vaccine, exposure to varicella, dermatomal zoster, and chickenpox., Results: Twenty-nine children, mean age 4.9 (SD 1.9) years, 45% receiving every-other-day steroids, received 2 vaccine doses. All patients seroconverted and had VZV antibody levels considered protective against breakthrough varicella (>or=5 gpELISA units) after 2 doses. At 2-year follow-up, all patients retained detectable antibody, and 91% (21 of 23) had levels >or=5 gpELISA units. There were no adverse events associated with vaccination., Conclusions: Varicella vaccine was generally well tolerated and highly immunogenic in children with nephrotic syndrome, including those on low-dose, alternate-day prednisone.
- Published
- 2003
- Full Text
- View/download PDF